Development of Highly Selective Epoxyketone-based Plasmodium Proteasome Inhibitors with Negligible Cytotoxicity

Jehad Almaliti, Pavla Fajtová, Jaeson Calla, Gregory LaMonte, Mudong Feng, Frances Rocamora, Sabine Ottilie, Evgenia Glukhov, Evžen Bouřa, Raymond T. Suhandynata, Jeremiah D. Momper, Michael K. Gilson, Elizabeth A. Winzeler, William H. Gerwick, Anthony J. O’DonoghuebioRxiv 2022 · DOI

TL;DR

This paper introduces a new class of epoxyketone-based compounds that potently inhibit the Plasmodium falciparum proteasome, the parasite responsible for malaria, while showing minimal toxicity to human cells. The lead compound, J-80, demonstrates over 2,600-fold selectivity for the parasite over human cells and shows promising efficacy in a mouse model, paving the way for new orally bioavailable antimalarial drugs.

What Problem Does This Paper Address?

Malaria remains a devastating global health issue, and the emergence of drug resistance to current treatments necessitates the development of novel antimalarial agents with new mechanisms of action. The Plasmodium falciparum proteasome is a crucial target for antimalarial therapy, as it is essential for parasite survival and replication. While proteasome inhibitors have shown promise, existing drugs are too toxic for malaria treatment. This paper aims to address this by developing highly selective proteasome inhibitors that specifically target the P. falciparum proteasome while sparing human cells, thereby overcoming the toxicity limitations of previous approaches.

Methods

The researchers employed a structure-based drug design approach, building upon a previously identified lead compound (carmaphycin B and its derivative J-18). They systematically modified different parts of the epoxyketone scaffold, including the P1, P3, and P4 positions, and explored various electrophilic warheads. Key techniques included:

  • Synthesis and SAR (Structure-Activity Relationship) Studies: Synthesizing a library of 32 new compounds with modifications at key positions and evaluating their in vitro potency against P. falciparum and cytotoxicity against human HepG2 cells.
  • Proteasome Inhibition Assays: Isolating the P. falciparum 20S proteasome and human constitutive 20S (c20S) proteasome to assess subunit-specific inhibition (β1, β2, β5) using fluorogenic reporter substrates. This allowed for the determination of kinetic parameters like $k_{inact}/K_{app}$.
  • Animal Models: Evaluating the therapeutic efficacy of the most promising compounds (J-71 and J-80) in a P. berghei luciferase mouse infection model to assess parasitemia reduction and survival rates.
  • Toxicity and Pharmacokinetic Studies: Assessing acute toxicity in mice and performing pharmacokinetic studies in rats to determine elimination half-lives.
  • Molecular Docking: Using computational modeling to visualize and understand the binding interactions of the most selective compounds within the P. falciparum proteasome, particularly focusing on the role of D-amino acids and specific amino acid residues in selectivity.

Datasets

Not explicitly discussed as distinct datasets in the paper. The primary "data" used for evaluation are the in vitro IC50 values against P. falciparum and HepG2 cells, and enzyme inhibition data for isolated proteasomes. The P. berghei mouse model serves as an in vivo evaluation system.

Key Insights and Ideas

  • The Power of D-Amino Acids at P3: Incorporating a D-amino acid at the P3 position of the epoxyketone scaffold is crucial for achieving high selectivity. This likely exploits a structural difference in the parasite proteasome's binding pocket that accommodates D-amino acids, while the human proteasome does not.
  • The Role of the P1 Phenylalanine: Replacing the P1 leucine with phenylalanine (or a difluorophenylalanine) significantly enhances selectivity by enabling favorable hydrophobic interactions within the P. falciparum proteasome's S1 pocket, a feature not present in the human proteasome.
  • Epoxyketone Warhead Superiority: Among the tested electrophilic warheads, the epoxyketone (EK) moiety proved to be superior in terms of both potency and selectivity compared to vinyl sulfones, boronic acid esters, enones, and aldehydes.
  • Dual Inhibition is Key: The paper highlights that dual inhibition of both β5 and β2 subunits of the proteasome is important for effective killing of P. falciparum across its life cycle, especially with short-term inhibitor administration.
  • Molecular Docking Reveals Inverted Binding Mode: Computational docking suggests that highly selective compounds adopt an "inverted binding mode," where the P3 and P4 groups occupy the S4 and S3 pockets, respectively. This arrangement allows for critical stabilizing interactions with residues like Ser27 in the P. falciparum proteasome, which are absent in the human proteasome (which has Ala at this position).

Key Results

  • Exceptional Selectivity: The lead compound, J-80, achieved an impressive selectivity index (SI) of over 2,600-fold for P. falciparum over human HepG2 cells.
  • Potent In Vitro Activity: J-80 inhibits P. falciparum replication with an IC50 of 8 nM.
  • Significant In Vivo Efficacy: In a mouse model of malaria, J-71 and J-80 significantly reduced parasitemia and prolonged survival by an average of 6 days, although they were not curative at the tested doses.
  • Favorable Pharmacokinetics: Compounds J-71 and J-80 exhibited reasonable elimination half-lives in rats (5.1 and 2.4 hours, respectively), suggesting potential for further optimization.
  • Subunit Selectivity: Compounds like J-71 and J-80 showed greater potency for the P. falciparum proteasome β5 subunit compared to the human c20S β5 subunit. J-80 exhibited a 177-fold selectivity for Pf20S β5 over c20S β5.

Limitations and Future Work

  • Not Curative in Mouse Model: While J-71 and J-80 showed significant improvements in survival, they were not curative in the P. berghei mouse model at the tested doses and schedules. This suggests that further optimization of dosing, delivery, or compound properties might be necessary for complete eradication.
  • Metabolic Stability: Metabolic profiling indicated that the hexanoyl chain in J-80 is a primary site of oxidation, and J-71 undergoes minor epoxide hydrolysis. These findings suggest that modifications to the P4 position might be required to extend the half-lives of these analogs.
  • Further Optimization: The authors state that the current epoxyketone inhibitors are "ideal starting compounds" and that the knowledge gained from this study will be used to develop compounds with improved pharmacokinetic properties for curative efficacy in animal models. This implies ongoing research to enhance potency, selectivity, and metabolic stability.
  • Oral Bioavailability: While the abstract mentions the goal of developing "orally bioavailable anti-malarial drugs," the current study primarily focuses on in vitro and in vivo efficacy, with limited discussion on oral formulation and absorption. This would be a key area for future investigation.

Summary updated

Abstract

ABSTRACT Here we present remarkable epoxyketone-based proteasome inhibitors with low nanomolar in vitro potency for blood-stage Plasmodium falciparum and low cytotoxicity for human cells. Our best compound has more than 2,600-fold greater selectivity for erythrocytic-stage P. falciparum over HepG2 cells, which is largely driven by the accommodation of the parasite proteasome for a d -amino acid in the P3 position and the preference for a difluorobenzyl group in the P1 position. These compounds also significantly reduce parasitemia in a P. berghei mouse infection model and prolong survival of animals by an average of 6 days. The current epoxyketone inhibitors are ideal starting compounds for orally bioavailable anti-malarial drugs.
BibTeX
@misc{almaliti2022development,
  author = {Jehad Almaliti and Pavla Fajtová and Jaeson Calla and Gregory LaMonte and Mudong Feng and Frances Rocamora and Sabine Ottilie and Evgenia Glukhov and Evžen Bouřa and Raymond T. Suhandynata and Jeremiah D. Momper and Michael K. Gilson and Elizabeth A. Winzeler and William H. Gerwick and Anthony J. O’Donoghue},
  title = {{Development of Highly Selective Epoxyketone-based Plasmodium Proteasome Inhibitors with Negligible Cytotoxicity}},
  year = {2022},
  doi = {10.1101/2022.08.06.502205},
  howpublished = {bioRxiv},
}
Figure